

November 17, 2011

ORIGIO a/s  
A world leader in Assisted Reproductive Technologies (ART)

**ORIGIO transfers own shares  
as part of the last deferred payment of MidAtlantic Diagnostics, Inc.**

ORIGIO a/s, a medtech company listed on the Oslo Stock Exchange (OSE: ORO), has reduced the number of own shares by 20,361 at an average share price of NOK 13.84 per share. The applied share price is the average closing price on the Oslo Stock Exchange for the period October 27 – November 4, 2011, which is the seven trading days prior to the anniversary closing date.

The shares have been transferred to Terry Fortino, CEO of ORIGIO Inc. as part of the last deferred payment in connection with the acquisition of MidAtlantic Diagnostics, Inc. that took place on September 30, 2008 (see press release dated September 26, 2008).

Subsequently, ORIGIO a/s holds 1,142 own shares and Terry Fortino, who is a primary insider, holds 106,297 ORIGIO shares.

*For further information, please contact:*

*Jesper Funding Andersen, CEO: +45 4073 0963 or email, [jfandersen@origio.com](mailto:jfandersen@origio.com)*

*Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or email, [jbrix@origio.com](mailto:jbrix@origio.com)*

**About ORIGIO a/s**

*ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families, MediCult Media, Humagen Pipets and MidAtlantic Devices, that cater for the broadest range of ART requirements. The medtech company ORIGIO, which is headquartered in Måløv, Denmark, and has subsidiaries in 10 countries, is listed on the Oslo Stock Exchange under the symbol, ORO. For further information, please visit [www.origio.com](http://www.origio.com).*

**Forward-Looking Statements**

*Certain statements in this announcement contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this announcement will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO's anticipated schedule. These factors, and other factors including, but not limited to, those described in ORIGIO's most recent annual report, could cause future results to differ materially from the expectations expressed in this announcement. The forward-looking statements contained in this announcement may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.*